Efficacy and Safety of AM-101 in the Treatment of Acute Inner Ear Tinnitus—A Double-Blind, Randomized, Placebo-Controlled Phase II Study
Open Access
- 1 April 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 35 (4) , 589-597
Abstract
To evaluate the efficacy and safety of intratympanic AM-101 in patients with persistent acute inner ear tinnitus after acute acoustic trauma, idiopathic sudden sensorineural hearing loss (ISSNHL), or acute otitis media. Prospective, double-blind, randomized, placebo-controlled study with follow-up visits on Days 7, 30, and 90. Twenty-eight European sites (academic tertiary referral centers and private ENT practices). 248 patients aged 16 to 65 years. Three intratympanic injections of AM-101 (0.27 or 0.81 mg/ml) or placebo over 3 consecutive days. Efficacy was assessed by changes in minimum masking level (MML; primary end point), loudness match, tinnitus loudness, tinnitus annoyance, and sleep difficulties on a 0 to 100 numerical rating scale, THI-12 questionnaire, and patient global impression of change. Safety was evaluated using the frequency of clinically relevant hearing deterioration and adverse events. The study overall failed to demonstrate a treatment benefit based on the change in MML. However, AM-101 0.81 mg/ml showed statistically significantly better improvement for tinnitus loudness, annoyance, sleep difficulties, and tinnitus impact in patients with tinnitus after noise trauma or otitis media. The subgroup of ISSNHL-related tinnitus patients did not show conclusive results. The study drug and I.T. injections were well tolerated. The study established proof of concept for AM-101 in the treatment of tinnitus arising from cochlear glutamate excitotoxicity. Patient-reported outcomes seem to be more relevant and reliable efficacy measures for assessing treatment-related changes in tinnitus than psychoacoustic tests.Keywords
This publication has 31 references indexed in Scilit:
- Tinnitus: pathology of synaptic plasticity at the cellular and system levelsFrontiers in Systems Neuroscience, 2012
- Tinnitus: network pathophysiology-network pharmacologyFrontiers in Systems Neuroscience, 2012
- Treatment options for subjective tinnitus: Self reports from a sample of general practitioners and ENT physicians within Europe and the USABMC Health Services Research, 2011
- Expression of tumor necrosis factor-α and interleukin-1β genes in the cochlea and inferior colliculus in salicylate-induced tinnitusJournal of Neuroinflammation, 2011
- Altered expression of middle and inner ear cytokines in mouse otitis mediaThe Laryngoscope, 2011
- Prevalence and Characteristics of Tinnitus among US AdultsThe American Journal of Medicine, 2010
- Tinnitus Outcomes AssessmentTrends in Amplification, 2008
- Blockade of Cochlear NMDA Receptors Prevents Long-Term Tinnitus during a Brief Consolidation Window after Acoustic TraumaNeural Plasticity, 2007
- The Inner Hair Cell Synaptic Complex: Physiology, Pharmacology and New Therapeutic StrategiesAudiology and Neurotology, 2002
- Chemical synaptic transmission in the cochleaProgress in Neurobiology, 1995